Trials / Completed
CompletedNCT03074006
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
Phase 1/2 Study of Vactosertib (TEW-7197) Monotherapy in Patients With Low or Intermediate Myelodysplastic Syndromes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- MedPacto, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, multicenter, phase 1/2 study of TEW-7197 in patients with low and intermediate risk of myelodysplastic syndrome (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TEW-7197 | 50mg tablets (doses will be determined through dose-escalation part) |
Timeline
- Start date
- 2018-01-04
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2017-03-08
- Last updated
- 2021-09-28
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03074006. Inclusion in this directory is not an endorsement.